Literature DB >> 14760536

Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Martin H Holtmann1, Peter R Galle.   

Abstract

INTRODUCTION: According to the current paradigm both ulcerative colitis (UC) and Crohn's disease (CD) result from a complex interplay of genetic susceptibility factors, environmental factors, alterations of the physiological intestinal flora and a defective regulation of the intestinal immune system. DISCUSSION: The objective of this review is to give an overview of these factors and mechanisms, including genetic, environmental and microbial factors, with special alterations of relevant cellular components of the intestinal immune system such as T cells, macrophages and epithelial cells will then be addressed. In addition, the most relevant animal model systems that have contributed to our current pathogenetic understanding will be introduced. Clinically, the natural course of UC with special reference to the risk of colorectal cancer will be addressed.
CONCLUSION: The elucidation of pathomechanisms at the level of the intestinal immune system provides the potential for novel, effective treatment strategies. Best surgical management of patients with UC, however, still remains a challenge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760536     DOI: 10.1007/s00423-003-0448-5

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  75 in total

Review 1.  Role of smoking in inflammatory bowel disease: implications for therapy.

Authors:  G A Thomas; J Rhodes; J T Green; C Richardson
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

2.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  The surgical management of toxic dilatation of the colon: a report of 28 cases and review of the literature.

Authors:  R J Strauss; G W Flint; N Platt; L Levin; L Wise
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

4.  Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis.

Authors:  M Boirivant; R Pica; R DeMaria; R Testi; F Pallone; W Strober
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

Authors:  J Satsangi; K I Welsh; M Bunce; C Julier; J M Farrant; J I Bell; D P Jewell
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

7.  Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.

Authors:  C K Weber; S Liptay; T Wirth; G Adler; R M Schmid
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

8.  The Vienna classification of gastrointestinal epithelial neoplasia.

Authors:  R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

9.  Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

Authors:  M O Blackstone; R H Riddell; B H Rogers; B Levin
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

10.  Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa.

Authors:  M Watanabe; Y Ueno; T Yajima; S Okamoto; T Hayashi; M Yamazaki; Y Iwao; H Ishii; S Habu; M Uehira; H Nishimoto; H Ishikawa; J Hata; T Hibi
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

View more
  9 in total

Review 1.  Do we really understand what the immunological disturbances in inflammatory bowel disease mean?

Authors:  Epameinondas V Tsianos; Konstantinos Katsanos
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

2.  Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument.

Authors:  Johanna Haapamäki; Risto P Roine; Harri Sintonen; Ulla Turunen; Martti A Färkkilä; Perttu E T Arkkila
Journal:  Qual Life Res       Date:  2010-04-02       Impact factor: 4.147

3.  Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action.

Authors:  B Sitohy; S Hammarström; A Danielsson; M-L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

4.  Crotoxin from Crotalus durissus terrificus is able to down-modulate the acute intestinal inflammation in mice.

Authors:  Caroline de Souza Almeida; Vinicius Andrade-Oliveira; Niels Olsen Saraiva Câmara; Jacqueline F Jacysyn; Eliana L Faquim-Mauro
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

Review 5.  Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.

Authors:  Giovanni C Actis; Rinaldo Pellicano
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-05-06

6.  Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.

Authors:  Niels Teich; Harald Grümmer; Eric Jörgensen; Thomas Liceni; Frank Holtkamp-Endemann; Tim Fischer; Susanne Hohenberger
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

7.  State-of-the-art surgery for ulcerative colitis.

Authors:  Shanglei Liu; Samuel Eisenstein
Journal:  Langenbecks Arch Surg       Date:  2021-08-28       Impact factor: 3.445

Review 8.  Shared decision-making in the management of patients with inflammatory bowel disease.

Authors:  Kai Song; Dong Wu
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

9.  Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.

Authors:  Jean Lachaine; Linnette Yen; Catherine Beauchemin; Paul Hodgkins
Journal:  BMC Gastroenterol       Date:  2013-01-30       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.